Specificity of striatal dopamine D1 system in humans: implications for clinical use of D1 receptor-agonists in Parkinson's disease

Satoshi Goto

doi:10.3389/fnhum.2023.1178616

Specificity of striatal dopamine D₁ system in humans: implications for clinical use of D₁ receptor-agonists in Parkinson's disease

Front Hum Neurosci. 2023 Apr 26:17:1178616. doi: 10.3389/fnhum.2023.1178616. eCollection 2023.

Author

Satoshi Goto^{1

2}

Affiliations

¹ Center for Drug Discovery and Development Sciences, Research Organization of Science and Technology, Ritsumeikan University, Kyoto, Japan.
² Department of Clinical Neuroscience, Institute of Biomedical Sciences, Tokushima University, Tokushima, Japan.

No abstract available

Keywords: Parkinson's disease; basal gangalia; dopamine D1 agonist; dopamine D1 receptors; drug therapy; patient; striatum.

Grants and funding

This work was supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan (grants-in-aid for Scientific Research nos. 24390223, 26461272, 26430054, and 16k10788), the Japan Agency for Medical Research and Development (AMED; no.16ek0109182h0001), and the Research Cluster of Tokushima University (no. 1702004).